NewsBenzinga報告:ヴィーキング・セラピューティクス、VK2735皮下注投与参加者の74%が13週間後にBMIカテゴリーを改善、プラセボ群は15%にとどまり、心代謝マーカーも改善したと発表(報告日:日曜日) 報告:ヴィーキング・セラピューティクス、VK2735皮下注投与参加者の74%が13週間後にBMIカテゴリーを改善、プラセボ群は15%にとどまり、心代謝マーカーも改善したと発表(報告日:日曜日) Benzinga 2026.11.16 05:21 (GMT+0) Open on Benzinga Other news South Korean Lawmaker Proposes Virtual Asset AML Bill, Exchanges Face Fines of Up to 100 Million Won Mark Carney Warns Canada Could Turn to China for Autos if Trade Talks With Trump Administration Fail: ‘Not Leverage. But Action, Reaction’ Italian Robotics Startup Mosaico Raises €7.5 Million Seed Round Ryan Cohen Wants Someone Who Can ‘Move Fast’ and ‘Own Results’ at GameStop as CEO Looks to Build His Next Big Move: Here’s How You Can Apply Are Wall Street Analysts Bullish on Eversource Energy Stock? Reported Saturday, Avexitide Meets Phase 3 LUCIDITY Primary Endpoint In Post-Bariatric Hypoglycemia, Cutting Level 2/3 Events 0.55 Per Week Versus 1.24 For Placebo, With No Treatment-Related Serious Adverse Events
Mark Carney Warns Canada Could Turn to China for Autos if Trade Talks With Trump Administration Fail: ‘Not Leverage. But Action, Reaction’
Ryan Cohen Wants Someone Who Can ‘Move Fast’ and ‘Own Results’ at GameStop as CEO Looks to Build His Next Big Move: Here’s How You Can Apply
Reported Saturday, Avexitide Meets Phase 3 LUCIDITY Primary Endpoint In Post-Bariatric Hypoglycemia, Cutting Level 2/3 Events 0.55 Per Week Versus 1.24 For Placebo, With No Treatment-Related Serious Adverse Events